Related Experiment Video
Updated: Sep 15, 2025

In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
Artificial intelligence in cardiovascular pharmacotherapy: applications and perspectives
Francesco Costa1,2,3, Juan Jose Gomez Doblas1,3,4, Arancha Díaz Expósito1,3
1Cardiology Department, University Hospital Virgen de la Victoria, Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga 29010, Spain.
Artificial intelligence (AI) enhances cardiovascular pharmacotherapy by optimizing drug selection and predicting outcomes. Further validation and standardized frameworks are crucial for safe clinical integration of AI in heart disease treatment.
Area of Science:
- Cardiovascular Medicine
- Artificial Intelligence in Healthcare
- Pharmacotherapy Optimization
Background:
- Artificial intelligence (AI) demonstrates significant potential in advancing cardiovascular pharmacotherapy.
- AI can optimize drug selection, predict treatment efficacy, and forecast adverse effects to improve patient outcomes.
- Current applications leverage machine learning and in silico modeling for personalized cardiovascular care.
Purpose of the Study:
- To systematically review the state-of-the-art applications of AI in cardiovascular pharmacotherapy.
- To describe the potential of AI in guiding treatment decisions, refining clinical trial methodologies, and supporting drug discovery.
- To highlight the need for robust validation and standardized frameworks for AI integration in clinical practice.
Main Methods:
- Review of current literature on AI applications in cardiovascular pharmacotherapy.
- Analysis of machine learning and in silico modeling techniques used in drug selection and efficacy prediction.
- Examination of AI's role in clinical trial design, real-world data analysis, and drug discovery.
Main Results:
- AI can identify patient subgroups likely to benefit from specific treatments, expedite drug discovery, and reduce costs.
- Computational methods facilitate drug interaction detection and personalized interventions using real-world data.
- AI shows promise in streamlining clinical trials through real-time patient responsiveness data and enhanced recruitment.
Conclusions:
- AI offers substantial benefits for cardiovascular pharmacotherapy, including improved patient outcomes and efficient drug development.
- Robust validation across diverse populations and addressing data quality, privacy, and bias are critical for generalizability and equity.
- Standardized frameworks for data management, model certification, and transparency are essential for safe and effective AI integration into clinical practice.
More Related Videos
07:51Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
Published on: September 26, 2018
04:09Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
Published on: October 10, 2018
Related Concept Videos
Cardiovascular Drugs: Classification based on Therapeutic Indications
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure VI: Adjunct Therapies
Cardiopulmonary Resuscitation IV: Pharmacological Management
Coronary Artery Disease V: Interprofessional Care
Cardiomyopathy V: Interprofessional Care